0 CHECKOUT

Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016

  • ID: 2624228
  • May 2016
  • Region: Global
  • 272 Pages
  • CurrentPartnering
1 of 4

FEATURED COMPANIES

  • AcuFocus
  • Bioniche Life Sciences
  • Fumapharm
  • MediGene
  • PBS Capital Management
  • SV Life Science
  • MORE

The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 report provides comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies.

The report provides a detailed understanding and analysis of how and why companies enter business, royalty financing agreements.

The focus of the report is on partnerships for royalty assets where partners have entered an agreement to dispose of or acquire said assets.

The report provides access to royalty financing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product

Revenue assets – also known as ‘synthetic royalties’, where a specialist investment company acquires the rights to a proportion of future revenue streams in return for a lump sum payment to the company

Understanding the flexibility of a prospective partner’s READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AcuFocus
  • Bioniche Life Sciences
  • Fumapharm
  • MediGene
  • PBS Capital Management
  • SV Life Science
  • MORE

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in royalty financing dealmaking

2.1. Introduction
2.2. Difference between royalty and revenue financing deals
2.3. Trends in royalty financing deals since 2010
2.3.1. Royalty financing dealmaking by year, 2010 to 2016
2.3.2. Royalty financing dealmaking by industry sector, 2010 to 2016
2.3.3. Royalty financing dealmaking by therapy area, 2010 to 2016
2.3.4. Royalty financing dealmaking most active, 2010 to 2016
2.4. Reasons for entering into royalty financing partnering deals
2.5 The emergence of royalty asset purchase deals
2.5.1. Primary players in royalty asset purchase deals
2.5.2. Recent royalty asset purchase deals
2.5.3. The role of big pharma in royalty buyback
2.5.4. The future of royalty asset purchase deals

Chapter 3 - Overview of royalty financing structure

3.1. Introduction
3.2. Anatomy of a royalty asset purchase agreement
3.3. Example royalty financing agreements
3.3.1. Case study 1: Xoma - UCB - Orbimed Advisors
3.3.2. Case study 2: Dyax - Paul Capital Healthcare
3.3.3. Case study 3: Royalty financing: Biocryst Pharmaceuticals -Shionogi
3.3.4. Case study 4: Royalty asset: TPG - CV Therapeutics

Chapter 4 - Leading royalty financing deals

4.1. Introduction
4.2. Top royalty financing deals by value

Chapter 5 - Top 10 most active royalty financing dealmakers

5.1. Introduction
5.2. Top 10 most active royalty financing dealmakers

Chapter 6 - Royalty financing contract documents 2010- 2016

Chapter 7 - Royalty financing agreement directory 2010- 2016

7.1. Introduction
7.2. Company A-Z
7.3. By industry sector
7.4. By therapy area

Appendices

Appendix 1 - Royalty financing references
Appendix 2 - Resources
Appendix 3 - Deal type definitions
Appendix 4 - Example royalty financing contract document

About

Table of Figures

Figure 1: Definition of royalty assets
Figure 2: Trends in royalty financing deal announcements, 2010- 2016
Figure 3: Royalty financing deals signed by industry sector, 2010 to 2016
Figure 4: Royalty financing deals signed by therapy area, 2010 to 2016
Figure 5: Royalty financing deals moast active companies, 2010 to 2016
Figure 6: Leading royalty asset investors
Figure 7: Leading royalty asset purchase agreements by value, 2010- 2016
Figure 8: Components of the royalty asset purchase deal structure
Figure 9: Top royalty financing deals by value since 2010
Figure 10: Most active royalty financing dealmakers 2010 to 2016
Figure 11: Online partnering resources
Figure 12: Deal type definitions
Figure 13: Royalty financing agreement for Qutenza

Note: Product cover images may vary from those shown
3 of 4

Accuitive Medical Ventures
AcuFocus
Aisling Capital
Alexza Pharmaceuticals
Allon Therapeutics
Amgen
Aradigm
Artes Biotechnology
Astellas Pharma Europe
AxoGen
Bausch & Lomb
Bess Royalty
Biogen Idec
Bioniche Life Sciences
CPPIB Credit Investments
Capital Royalty
Children's Hospital of Philadelphia
Clarus Ventures
Corcept Therapeutics
Cowen Healthcare Royalty Partners
DRI Capital
Deerfield Management
Dendreon
DepoMed
Dyax
Elan
Forest Laboratories
Fumapharm
Furiex Pharma
Glaxo Group
GlaxoSmithKline
Hana Biosciences
Healthcare Royalty Partners
Human Genome Sciences
InSite Vision
Indevus Pharmaceuticals
Innexus
Isar Pharma
LifeCycle Pharma
Litmus
MediGene
Medtronic
MiddleBrook Pharmaceutical
NPS Pharmaceuticals
Nektar Therapeutics
NeurogesX
New York University
Northwestern University
Novo
Nuron Biotech
Ophthotech
Orbimed Advisors
PBS Capital Management
PDL BioPharma
Paul Capital Healthcare
Pharmakon Advisors
Phase III Development Company
Plethora Solutions
Pozen
Quest Diagnostics
Royalty Pharma
Royalty Securitization Trust
Rush University Medical Center
SV Life Science
SWK Funding
SkyePharma
Spepharm Holding
Stereotaxis
Suneva Medical
Supernus Pharmaceuticals
TearScience
The Carlyle Group
Theravance
Titan Pharmaceuticals
UCB
Unilife
Vernalis
Versant Ventures
Vertex Pharmaceuticals
Vivione Biosciences
Vivus
Zogenix
ZymoGenetics

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

  • Quick Help: A copy of the report will be emailed to you and a copy will be shipped to you in CD ROM format. The Electronic copy is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • bioCSL
  • Abbott Laboratories Ltd.
  • Radiometer Limited
  • Genfit
  • Focus Diagnostics Inc.
  • Genomic Health Inc.